Source: yahoo_news
Source ID: yahoo:1b48b7e354dac93f612dc87cb3388d2f:PBLS
URL: https://finance.yahoo.com/healthcare/articles/parabilis-medicines-presents-updated-phase-124500025.html?.tsrc=rss
Symbol: (PBLS)
Published: 2026-10-24 08:45:00 EDT
Time precision: minute
Title: Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL Phase 3 registrational trial, with initiation planned in the first half of 2027 and topline results anticipated in 2029Co